Abstract：【Objective】To investigate the clinical efficacy of bevacizumab combined with carboplatin and paclitaxel (TC) regimen in the treatment of ovarian cancer patients and its effect on serum levels of human epididymal protein 4 (HE4) and carbohydrate antigen 125 (CA125). 【Methods】A total of 126 ovarian cancer patients admitted to our hospital from February 2016 to July 2022 were randomly divided into an observation group (receiving bevacizumab combined with TC regimen treatment) and a control group (receiving TC regimen treatment) using a random number table method, with 63 patients in each group. The clinical efficacy, incidence of adverse reactions, immune function indicators (CD3+, CD4+, CD8+T lymphocyte levels), and serum HE4 and CA125 levels were compared between two groups. After a one-year follow-up, the survival status of the two groups was compared. 【Results】The objective remission rate and disease control rate of the observation group were significantly higher than those of the control group, and the difference was statistically significant (P<0.05). After treatment, the levels of CD3+, CD4+, and CD8+in both groups decreased (P<0.05), but there was no statistically significant difference in the above indicators between the two groups (P>0.05). After treatment, the levels of serum HE4 and CA125 in both groups decreased (P<0.05); And the serum levels of HE4 and CA125 in the observation group were lower than those in the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two treatment groups within 4 cycles. After a one-year follow-up, the survival rate of the observation group was 65.08% (41/63), which was significantly different from the control group's 44.44% (28/63) (P<0.05). 【Conclusion】The combination of bevacizumab and TC regimen has significant therapeutic effects on ovarian cancer patients, significantly reducing serum HE4 and CA125 levels without increasing the impact on immune function. It is safe and reliable, and worthy of clinical promotion and application.
朱雨. 贝伐珠单抗联合TC方案治疗卵巢癌患者的临床疗效及对患者血清HE4、CA125水平的影响[J]. 医学临床研究, 2025, 42(4): 604-607.
ZHU Yu. Clinical Efficacy of Bevacizumab Combined with TC Regimen in the Treatment of Ovarian Cancer Patients and its Impact on Serum HE4 and CA125 Levels. JOURNAL OF CLINICAL RESEARCH, 2025, 42(4): 604-607.
[1] BLUMGART L H, THOMPSON J N. The management of benign strictures of the bile duct[J].Curr Probl Surg,1987,24(1):1-66. [2] 冯延,徐燕,梁涛,等. 高危子宫内膜癌卡铂和紫杉醇联合化疗后静脉血栓发生情况分析[J].中国妇产科临床杂志,2022,23(3):284-286. [3] LA VECCHIA C. Ovarian cancer: epidemiology and risk factors[J].Eur J Cancer Prev,2017,26(1):55-62. [4] SIMMONS A R, CLARKE C H, BADGWELL D B, et al. Validation of a biomarker panel and longitudinal biomarker performance for early detection of ovarian cancer[J].Int J Gynecol Cancer,2016,26(6):1070-1077. [5] 万德森.临床肿瘤学[M].4版.北京:科学出版社,2015:282-289. [6] EISENHAUER E A , THERASSE P , BOGAERTS J,et al.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J].Eur J Cancer,2009, 45(2):228-247. [7] BOYD M R, PAULL K D. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen[J].Drug Develop Res,2010,34(2):91-109. [8] 曹士红. 热疗联合TC化疗方案对晚期卵巢癌患者CA125水平及肿瘤直径的影响[J].实用癌症杂志,2021,36(9):1494-1496. [9] TEWARI K S, BURGER R A, ENSERRO D, et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer[J].J Clin Oncol,2019,37(26):2317-2328. [10] 郎晓东,王虹,朱建凤. 贝伐珠单抗联合TC化疗方案对卵巢癌患者血清炎性因子及肿瘤标志物的影响[J].反射疗法与康复医学,2023,4(11):178-181. [11] 王亚茹,邵娟,刘新美. 贝伐珠单抗联合TP方案治疗卵巢癌的临床研究[J].中国性科学,2020,29(12):61-64. [12] ZHANG M H, CHENG S S, JIN Y, et al. Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer[J].Biochim Biophys Acta Rev Cancer,2021,1875(2):188503. [13] 张善存,张江霞,王云龙. 贝伐珠单抗联合TC方案治疗晚期卵巢癌患者血清AFP、CA125及远期预后的影响[J].实用癌症杂志,2021,36(6):1000-1003. [14] 张楠,郑虹,高雨农,等. 贝伐珠单抗治疗初治卵巢癌患者的真实世界研究[J].肿瘤药学,2023,13(1):69-76. [15] 康凌,李小华,宋晓玲. 复方大七气汤联合TC方案治疗对晚期卵巢癌血清肿瘤标志物及免疫功能的影响[J].中华中医药学刊,2023,41(3):38-41.
2025, Vol. 42 
